Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 9, 2026 · Filed Nov 10, 2026
A major shareholder of Bolt Biotherapeutics paid $319K out of pocket for Bolt Biotherapeutics shares. Shares held went up 12% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$319,000
Shares × reported transaction price
$100K–$500K
+12.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
90 days after results of Aug 11, 2026, 3 days before results of Nov 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $6.43 on Nov 9, 2026, 102% above its 52-week low and 9% below its high, after an 86% rise over the previous 30 trading days
52-week range $3.18 (Aug 18, 2026) to $7.09 (Jan 27, 2026), 83% of the way up, from 251 adjusted closes. 30 trading days earlier: $3.46 on Sep 28, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Bought 90 days after BOLT's last results announcement; 95% of its insiders' purchases since 2021 were made within 30 days after one. Traded 3 days before BOLT reported its results (Nov 12, 2026). The first open-market purchase by any BOLT insider since Dec 2023
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Insider filing
Traded Oct 23 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Coastlands Capital LP, 10% owner's past purchases, 90 days after disclosure: 4 buys, median +18.4 pts vs S&P 500, beat it 3 of 4 times. Past results, not a forecast.
